References
- Fitzpatrick TB, Johnson RA, Wolff K, et al. Psoriasis and ichthyosiform dermatoses. In: Color atlas and synopsis of clinical dermatology: common and serious diseases. 4th ed. New York: McGraw-Hill, 2001: 350–69
- Habif TP. Psoriasis and other papulosquamous diseases. In: Clinical dermatology: a color guide to diagnosis and therapy. 4th ed. St Louis: Mosby, 2004: 209–39
- Drew GS. Psoriasis. Prim Care 2000; 27(2): 385–406
- Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46(6): 850–60
- Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46(1): 1–23
- Lebwohl M, Ali S. Treatment of psoriasis. Part 1: topical therapy and phototherapy. J Am Acad Dermatol 2001; 45(4): 487–98
- Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician 2000; 61(3): 725–36
- Taylor CR, Baron E. Psoriasis, Guttate. Available at: http://www.emedicine.com/derm/topic361.htm. Accessed Feb 2, 2005
- Owen CM, Chalmers RJ, O'Sullivan T, et al. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev 2000; (2): CD001976
- Chalmers RJ, O'Sullivan T, Owen CM, et al. Interventions for guttate psoriasis. Cochrane Database Syst Rev 2000; (2): CD001213
- Lebwohl M, Ali S. Treatment of psoriasis. Part 2: systemic therapies. J Am Acad Dermatol 2001; 45(5): 649–61
- Lebwohl M. Advances in psoriasis therapy. Dermatol Clin 2000; 18(1): 13–9
- Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337(8735): 193–6 [Erratum, Lancet 1991; 337(8747): 988]
- Psoriasis treatments. Bandolier 1998; 51–5. Available at: http://www.jr2.ox.ac.uk/bandolier/band51/b51-5.html. Accessed Jan 3, 2005
- Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48(5): 760–7
- Behrens S, Grundmann-Kollmann M, Schiener R, et al. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000; 42(3): 493–5
- Stern RS; PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44(5): 755–61
- Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47(6): 821–33
- Ellis C, Krueger GG. Alefacept significantly reduces psoriasis area and severity in people with chronic plaque psoriasis. Evidence-based Healthcare: a Scientific Approach to Health Policy 2002; 6(1): 39–40. Available at: http://home.mdconsult.com/das/article/body/1/jorg=joumal&.source=&sp-12427388&sid=1825. Accessed Jan 3, 2005